Patents by Inventor Mario RENTSCH

Mario RENTSCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Composition
    Publication number: 20220233515
    Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
    Type: Application
    Filed: February 10, 2022
    Publication date: July 28, 2022
    Inventors: Geoffrey GOGNIAT, Saran KUMAR, Ulrich MEIER, Mario RENTSCH
  • Pharmaceutical composition
    Patent number: 11291661
    Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 5, 2022
    Assignee: Novartis AG
    Inventors: Geoffrey Gogniat, Saran Kumar, Ulrich Meier, Mario Rentsch
  • Pharmaceutical Composition
    Publication number: 20210169866
    Abstract: The The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 10, 2021
    Inventors: Geoffrey GOGNIAT, Saran KUMAR, Ulrich MEIER, Mario RENTSCH